Among the titans of finance, a bullish phenomenon has emerged in the world of Johnson & Johnson. An exploration of the options activity surrounding Johnson & Johnson (JNJ) uncovered a dozen extraordinary trades.
Delving into the intricate details, a staggering 75% of traders exuded bullish sentiments, while 25% leaned towards the bearish end. Out of the highlighted trades, 8 were puts amounting to $448,993, and 4 were calls valued at $249,736.
Unveiling the Price Target Dynamics
Analysis of the Volume and Open Interest within these contracts reveals a concerted effort by the market whales to pin Johnson & Johnson’s price between $120.0 and $165.0 over the past three months.
Insights into Volume & Open Interest Trends
In today’s strategic trade landscape, Johnson & Johnson options boast an average open interest of 1807.17, with a total volume of 2,748.00. Examining the chart overlaying call and put option volumes against open interests for significant trades in Johnson & Johnson, within the strike price range from $120.0 to $165.0, over the last 30 days, reveals fascinating patterns.
The Pulse of Johnson & Johnson’s 30-Day Option Volume & Interest
Noteworthy Revelations in Options Activity:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| JNJ | CALL | SWEEP | BEARISH | 05/17/24 | $165.00 | $135.1K | 3.9K | 556 |
| JNJ | PUT | SWEEP | BULLISH | 01/16/26 | $150.00 | $119.0K | 1.1K | 276 |
| JNJ | PUT | SWEEP | BULLISH | 01/16/26 | $150.00 | $103.1K | 1.1K | 353 |
| JNJ | PUT | SWEEP | BULLISH | 01/16/26 | $150.00 | $50.4K | 1.1K | 57 |
| JNJ | PUT | SWEEP | BULLISH | 06/20/25 | $150.00 | $46.9K | 1.4K | 141 |
Exploring the World of Johnson & Johnson
Johnson & Johnson reigns as the globe’s largest and most diverse healthcare colossus. With three distinct divisions comprising pharmaceuticals, medical devices and diagnostics, and consumer goods, the company’s legacy thrives. The pharmaceutical and device units command almost 80% of sales and fuel a substantial portion of the firm’s financial inflow.
An extensive portfolio targeting immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases shapes the drug division’s essence, while the device segment excels in orthopedics, surgical tools, vision care, and selected niche areas. The consumer division, catering to baby care, beauty, oral care, OTC drugs, and women’s health, is undergoing a transformative journey slated for completion by 2023 under the rebranded banner of Kenvue. Over half of Johnson & Johnson’s revenue stems from the United States.
A foray into the options landscape of Johnson & Johnson lays the groundwork to delve further into the company’s ongoing trajectory.
The Current Position of Johnson & Johnson
- With a trading volume of 3,552,032, JNJ’s shares show a 0.4% ascent, reaching $160.48.
- RSI indicators suggest a potential overbought scenario for the underlying stock.
- Anticipated earnings release looms on the horizon, scheduled in 42 days.
Expert Opinions on Johnson & Johnson
In the last month, a cohort of three professional analysts weighed in on the stock, presenting an average price target of $203.67.
- Adopting a prudent stance, an analyst from RBC Capital downgraded the rating to Outperform, setting a target price of $181.
- In a contemplative move, an analyst from Cantor Fitzgerald revised the rating to Overweight while adjusting the price target to $215.
- Similarly, an analyst from Cantor Fitzgerald downgraded the action to Overweight, setting a price target of $215.
Options stand as a realm of heightened risk compared to traditional stock trading, yet they offer amplified profit potential. Seasoned options enthusiasts navigate this perilous terrain through continual education, strategic entry and exit strategies, consideration of multiple indicators, and vigilant market monitoring.